SALL4表达水平与卵巢癌患者化疗后疾病进展风险的相关性

目的 探讨人类婆罗双树样基因4（spalt-like transcription factor 4,SALL4）表达水平与卵巢癌患者化疗后疾病进展风险的相关性。方法 选取2019年1月至2021年10月于宁波大学附属人民医院进行化疗的94例卵巢癌患者为研究对象进行随访,截至2022年5月1日,最终89例获得随访,根据化疗后是否出现疾病进展分为进展组（n=49）和无进展组（n=40）。收集患者的临床资料,通过单因素和多因素Logistic分析卵巢癌患者化疗后疾病进展风险的影响因素。结果 两组糖类抗原125（carbohydrate antigen 125,CA125）、SALL4、人附睾蛋白4（human epididymal protein 4,HE4）、中性粒细胞与淋巴细胞的比率（neutrophil to lymphocyte ratio,NLR）比较,差异均有统计学意义（P<0.05）;单因素Logistic分析显示,CA125、SALL4、HE4、NLR为影响卵巢癌化疗后疾病进展的相关因素。多因素Logistic分析显示,SALL4、HE4、NLR为卵巢癌化疗后疾病进展的独立危险因素。受试者操作特征曲线显示,SALL4[曲线下面积（area under the curve,AUC）=0.902,95%置信区间（confidence interval,CI）：0.830~0.974]、HE4（AUC=0.833,95%CI：0.739~0.926）、NLR（AUC=0.753,95%CI：0.653~0.853）能够预测卵巢癌患者化疗后疾病进展风险。结论 SALL4、HE4、NLR与卵巢癌患者化疗后疾病进展风险密切相关,且可预测卵巢癌患者化疗后疾病进展风险。

Correlation of SALL4 expression level with risk of disease progression in ovarian cancer patients undergoing chemotherapy

Objective To investigate the correlation between the expression levels of the human spalt-like transcription factor 4 (SALL4) and the risk of disease progression in ovarian cancer patients treated with chemotherapy. Methods A total of 94 ovarian cancer patients treated with chemotherapy at People''s Hospital Affiliated to Ningbo University from January 2019 to October 2021 were selected for follow-up, and as of May 1st, 2022, 89 cases were finally followed up and divided into progressive (n=49) and non-progressive (n=40) groups according to whether disease progression occurred after chemotherapy. Clinical data of the patients were collected and factors influencing the risk of disease progression after chemotherapy in ovarian cancer patients were analysed by univariate and multifactorial Logistic analysis. Results The differences in carbohydrate antigen 125 (CA125), SALL4, human epididymal protein 4 (HE4) and neutrophil to lymphocyte ratio (NLR) between the two groups were statistically significant (P<0.05). Univariate Logistic analysis showed that CA125, SALL4, HE4 and NLR were relevant factors affecting disease progression after chemotherapy for ovarian cancer. Multi-factor Logistic analysis showed that SALL4, HE4 and NLR were independent risk factors for disease progression after chemotherapy for ovarian cancer. The receiver operator characteristic curve showed that SALL4 [area under the curve (AUC)=0.902, 95% confidence interval (CI): 0.830-0.974], HE4 (AUC=0.833, 95%CI: 0.739-0.926), NLR (AUC=0.753, 95%CI: 0.653-0.853) were able to predict the risk of disease progression after chemotherapy in ovarian cancer patients. Conclusion SALL4, HE4 and NLR are closely associated with and predict the risk of disease progression after chemotherapy in patients with ovarian cancer.